Asterand’s subsidiary BioSeek signs agreement with Cellzome

Asterand has announced that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year agreement with Cellzome.

Asterand, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, has announced that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year agreement with Cellzome. 

Under the agreement, BioSeek will apply its unique BioMAP predictive human disease models to support and advance Cellzome’s discovery projects in the treatment of inflammatory diseases.

Oliver Rausch, Vice President Biology at Cellzome , noted:  “We are delighted to partner with BioSeek for access to their proprietary human biology models. The BioMAP platform will allow us to receive early insight into the human pharmacological and toxicological properties of our small molecules, enabling us to develop safer and more effective treatments for inflammation.”

Asterand’s CEO, Martyn Coombs, commented:&